Professor Julien Baruteau is a Consultant Metabolic Paediatrician at Great Ormond Street Hospital for Children in London, specialising in inherited metabolic disorders and rare genetic diseases. His clinical and research work focuses on understanding the biological mechanisms behind metabolic conditions and developing innovative treatments, including gene therapies.

His area of expertise, paediatric metabolic medicine, covers disorders in which genetic or biochemical abnormalities affect how the body processes substances such as proteins, fats, carbohydrates, or cellular energy. These conditions can affect multiple organs and may require highly specialised diagnosis, monitoring, nutritional management, medication, and advanced therapeutic approaches.

Professor Baruteau is particularly involved in research into inherited metabolic disorders and novel therapies. GOSH identifies him as a Consultant Metabolic Paediatrician and highlights his work developing gene therapies for rare diseases. In September 2026, GOSH announced his promotion to professor by University College London.

One of his major research areas involves urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency. These rare inherited disorders can cause dangerous accumulation of ammonia and may require specialist treatment. GOSH reported that Professor Baruteau led a groundbreaking clinical trial involving a new investigational gene therapy for OTC deficiency.

The research illustrates the growing role of precision medicine in rare paediatric disease. Instead of relying only on treatments that control symptoms, gene-based approaches aim to address underlying genetic mechanisms. Such therapies remain highly specialised and are generally available only through appropriate clinical programmes or research studies.

Professor Baruteau also works closely with researchers at the UCL Great Ormond Street Institute of Child Health. GOSH lists him as a clinician scientist and research group leader, with work centred on inherited metabolic diseases and the development of new treatments.

His research has included innovative approaches involving messenger RNA and other advanced therapeutic technologies. Earlier GOSH research reported his involvement in work investigating mRNA-based treatment strategies for rare inherited metabolic disease, demonstrating the broader research programme surrounding novel therapies at GOSH and UCL.

For children with rare metabolic conditions, diagnosis can require detailed biochemical testing, genetic analysis, specialist imaging, and coordinated assessment across several paediatric disciplines. Treatment plans are individualised according to the specific disorder, symptoms, age, genetic findings, and available therapies.

Professor Baruteau's clinical and academic role also reflects the importance of collaboration between hospital-based medicine and laboratory research. Rare metabolic disorders often affect relatively small patient populations, making specialist centres and international research collaboration important for developing evidence and evaluating new treatments.

His work contributes to GOSH's wider focus on gene, stem, and cellular therapies for children with rare and complex diseases. The hospital has maintained a major research programme in advanced therapies and has been involved in gene-therapy research for more than two decades.

Families seeking specialist metabolic care can benefit from having comprehensive medical records, previous genetic or biochemical results, medication information, and relevant imaging available for specialist assessment. The appropriate pathway depends on the child's condition and whether the required service is available through clinical care or a research programme.

For international patients, Great Ormond Street Hospital should be contacted directly to confirm referral requirements, appointment availability, eligibility for specialist metabolic services, and whether particular gene-therapy programmes are open to external patients.